<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01135576</url>
  </required_header>
  <id_info>
    <org_study_id>AGL2006/09519/ALI</org_study_id>
    <nct_id>NCT01135576</nct_id>
  </id_info>
  <brief_title>Iron Fortified Beverages and Application in Women Predisposed to Anemia</brief_title>
  <acronym>FeDrink</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>National Research Council, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Innovation, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grupo Leche Pascual</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Madrid Salud, Madrid, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Research Council, Spain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  The objective of the study is to know if consumption of an iron fortified fruit juice
           containing micronized iron pyrophosphate, is useful to increase iron status in women
           predisposed to iron deficiency anemia.

        -  A secondary objective is to know if consumption of this iron fortified fruit juice
           modifies bone remodelling.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Ferritin</measure>
    <time_frame>monitored during 16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum transferrin</measure>
    <time_frame>monitored during 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>monitored during 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum iron</measure>
    <time_frame>monitored during 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transferrin saturation</measure>
    <time_frame>monitored during 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>soluble transferrin receptor</measure>
    <time_frame>monitored during 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>zinc protoporphyrin</measure>
    <time_frame>monitored during 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total red blood cells</measure>
    <time_frame>monitored during 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>monitored during 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular volume</measure>
    <time_frame>monitored during 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red blood cell distribution width</measure>
    <time_frame>monitored during 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25-hydroxycholecalciferol</measure>
    <time_frame>monitored during 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alkaline phosphatase bone-isoenzyme (ALP)</measure>
    <time_frame>monitored during 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum cross-linked N-telopeptide of type I collagen (NTx)</measure>
    <time_frame>monitored during 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>monitored during 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-cholesterol</measure>
    <time_frame>monitored during 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-cholesterol</measure>
    <time_frame>monitored during 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>monitored during 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum triacylglycerols</measure>
    <time_frame>monitored during 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-chol/HDL-chol</measure>
    <time_frame>monitored during 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-chol/HDL-chol</measure>
    <time_frame>monitored during 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>monitored during 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>monitored during 16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Iron-deficiency Anemia</condition>
  <arm_group>
    <arm_group_label>Placebo juices</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Consumption of non-iron fortified fruit juices as part of the usual diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iron fortified fruit juices</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consumption of iron fortified fruit juices as part of the usual diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>non-fortified fruit juices consumed as part of the usual diet</intervention_name>
    <arm_group_label>Placebo juices</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Iron fortified fruit juice</intervention_name>
    <description>Consumption of micronized iron pyrophosphate supplemented fruit juices as part of the usual diet</description>
    <arm_group_label>Iron fortified fruit juices</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women

          -  non-smoker

          -  non-pregnant

          -  non-breastfeeding

          -  serum ferritin &lt;40 ng/ml

          -  hemoglobin&gt;=11g/dl

        Exclusion Criteria:

          -  Serum Ferritin &gt;=40 ng/ml

          -  Hemoglobin &lt;11g/dl

          -  Amenorrhea

          -  Menopause

          -  Iron deficiency anemia

          -  Thalassemia

          -  Hemochromatosis

          -  Blood donors

          -  Chronic gastric diseases

          -  Renal diseases

          -  Eating disorders

          -  Allergy to any component of the study juices

          -  Consumption of iron or ascorbic acid supplements within 4 month prior to participating
             in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Navas-Carretero S, Pérez-Granados AM, Schoppen S, Sarria B, Carbajal A, Vaquero MP. Iron status biomarkers in iron deficient women consuming oily fish versus red meat diet. J Physiol Biochem. 2009 Jun;65(2):165-74.</citation>
    <PMID>19886395</PMID>
  </reference>
  <reference>
    <citation>Navas-Carretero S, Pérez-Granados AM, Schoppen S, Vaquero MP. An oily fish diet increases insulin sensitivity compared to a red meat diet in young iron-deficient women. Br J Nutr. 2009 Aug;102(4):546-53. doi: 10.1017/S0007114509220794. Epub 2009 Feb 12.</citation>
    <PMID>19210857</PMID>
  </reference>
  <reference>
    <citation>Navas-Carretero S, Pérez-Granados AM, Sarriá B, Vaquero MP. Iron absorption from meat pate fortified with ferric pyrophosphate in iron-deficient women. Nutrition. 2009 Jan;25(1):20-4. doi: 10.1016/j.nut.2008.07.002. Epub 2008 Aug 26.</citation>
    <PMID>18752926</PMID>
  </reference>
  <reference>
    <citation>Navas-Carretero S, Pérez-Granados AM, Sarriá B, Carbajal A, Pedrosa MM, Roe MA, Fairweather-Tait SJ, Vaquero MP. Oily fish increases iron bioavailability of a phytate rich meal in young iron deficient women. J Am Coll Nutr. 2008 Feb;27(1):96-101.</citation>
    <PMID>18460487</PMID>
  </reference>
  <reference>
    <citation>Navas-Carretero S, Sarriá B, Pérez-Granados AM, Schoppen S, Izquierdo-Pulido M, Vaquero MP. A comparative study of iron bioavailability from cocoa supplemented with ferric pyrophosphate or ferrous fumarate in rats. Ann Nutr Metab. 2007;51(3):204-7. Epub 2007 Jun 18.</citation>
    <PMID>17587790</PMID>
  </reference>
  <reference>
    <citation>Sarria B, Navas-Carretero S, Lopez-Parra AM, Perez-Granados AM, Arroyo-Pardo E, Roe MA, Teucher B, Vaquero MP, Fairweather-Tait SJ. The G277S transferrin mutation does not affect iron absorption in iron deficient women. Eur J Nutr. 2007 Feb;46(1):57-60. Epub 2007 Jan 5.</citation>
    <PMID>17206377</PMID>
  </reference>
  <reference>
    <citation>Navas-Carretero S, Pérez-Granados AM, Sarriá B, Schoppen S, Vaquero MP. Iron bioavailability from pate enriched with encapsulated ferric pyrophosphate or ferrous gluconate in rats. Food Sci Tech Int 13:159-163, 2007.</citation>
  </reference>
  <reference>
    <citation>Toxqui L, De Piero A, Courtois V, Bastida S, Sánchez-Muniz FJ, Vaquero MP. [Iron deficiency and overload. Implications in oxidative stress and cardiovascular health]. Nutr Hosp. 2010 May-Jun;25(3):350-65. Review. Spanish.</citation>
    <PMID>20593115</PMID>
  </reference>
  <results_reference>
    <citation>Blanco-Rojo R, Pérez-Granados AM, Toxqui L, Zazo P, de la Piedra C, Vaquero MP. Relationship between vitamin D deficiency, bone remodelling and iron status in iron-deficient young women consuming an iron-fortified food. Eur J Nutr. 2013 Mar;52(2):695-703. doi: 10.1007/s00394-012-0375-8. Epub 2012 May 23.</citation>
    <PMID>22618893</PMID>
  </results_reference>
  <results_reference>
    <citation>Blanco-Rojo R, Pérez-Granados AM, Toxqui L, González-Vizcayno C, Delgado MA, Vaquero MP. Efficacy of a microencapsulated iron pyrophosphate-fortified fruit juice: a randomised, double-blind, placebo-controlled study in Spanish iron-deficient women. Br J Nutr. 2011 Jun;105(11):1652-9. doi: 10.1017/S0007114510005490. Epub 2011 Feb 8.</citation>
    <PMID>21303569</PMID>
  </results_reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2010</study_first_submitted>
  <study_first_submitted_qc>June 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2010</study_first_posted>
  <last_update_submitted>December 21, 2012</last_update_submitted>
  <last_update_submitted_qc>December 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Research Council, Spain</investigator_affiliation>
    <investigator_full_name>M Pilar Vaquero</investigator_full_name>
    <investigator_title>Scientific Researcher</investigator_title>
  </responsible_party>
  <keyword>Ferric pyrophosphate</keyword>
  <keyword>Fortification</keyword>
  <keyword>Fruit juice</keyword>
  <keyword>Functional food</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>iron status</keyword>
  <keyword>Women</keyword>
  <keyword>iron-deficiency anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

